Cart
sales@molnova.com
FTO-IN-3
CAS No. 2585198-87-2
FTO-IN-3( —— )
Catalog No. M28284 CAS No. 2585198-87-2
FTO-IN-3 is a FTO inhibitor that impair self-renewal in glioblastoma stem cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 170 | In Stock |
|
| 5MG | 187 | In Stock |
|
| 10MG | 301 | In Stock |
|
| 25MG | 483 | In Stock |
|
| 50MG | 631 | In Stock |
|
| 100MG | 854 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameFTO-IN-3
-
NoteResearch use only, not for human use.
-
Brief DescriptionFTO-IN-3 is a FTO inhibitor that impair self-renewal in glioblastoma stem cells.
-
DescriptionFTO-IN-3 is a FTO inhibitor that impair self-renewal in glioblastoma stem cells.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorAntibacterial|S. aureus|E. coli
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2585198-87-2
-
Formula Weight258.3
-
Molecular FormulaC12H10N4OS
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (387.15 mM)
-
SMILESCOc(nc1)ncc1-c(cc1)cc2c1nc(N)s2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Alyar, S., et al. Quantitative structure–activity relationships studies for prediction of antimicrobial activity of synthesized disulfonamide derivatives. Med Chem Res 20, 175–183 (2011).
molnova catalog
related products
-
(Rac)-IBT6A
(Rac)-IBT6A is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib and can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.
-
Dynorphin B (1-9)
Dynorphin B (1-9) is a neuropeptide and N-terminal cleavage product of dynorphin B. The formation of dynorphin B (1-9) is blocked by N-ethylmaleimide (NEM), a non-selective inhibitor of cysteine peptidases.
-
ASC-JM-17
ASC-JM-17 is an activator of both Nrf1 and Nrf2 proteins. ASC-JM17 acts on Nrf1, Nrf2 and Hsf1 to increase the expression of proteasome subunits, antioxidant enzymes and molecular chaperones.
